Chimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 AUD | +5.88% | +12.50% | -48.57% |
05-22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
05-20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.57% | 9.68M | |
+16.42% | 122B | |
+19.02% | 113B | |
+2.77% | 22.66B | |
-16.20% | 21.34B | |
-39.57% | 16.92B | |
-11.63% | 16.68B | |
-16.17% | 16.61B | |
+2.68% | 13.62B | |
+21.16% | 11.04B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director